Emergent BioSolutions
EBS
$4.72
Share price
-0.84%
Change (1 day)
-42.23%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $1.13 B
According to Emergent BioSolutions 's latest financial reports the company's total liabilities are $1.13 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $1.17 B | -34% |
| 2022-12-31 | $1.77 B | 32.12% |
| 2021-12-31 | $1.34 B | -6.27% |
| 2020-12-31 | $1.43 B | 15.93% |
| 2019-12-31 | $1.23 B | 1.67% |
| 2018-12-31 | $1.21 B | 671.69% |
| 2017-12-31 | $0.15 B | -57.77% |
| 2016-12-31 | $0.37 B | -0.94% |
| 2015-12-31 | $0.37 B | -2.08% |
| 2014-12-31 | $0.38 B | 180.43% |
| 2013-12-31 | $0.13 B | 12.58% |
| 2012-12-31 | $0.12 B | -6.17% |
| 2011-12-31 | $0.13 B | 2.67% |
| 2010-12-31 | $0.12 B | 25.66% |
| 2009-12-31 | $0.10 B | 10.32% |
| 2008-12-31 | $91.43 M | -10.66% |
| 2007-12-31 | $0.10 B | 2.57% |
| 2006-12-31 | $99.78 M | 145.8% |
| 2005-12-31 | $40.59 M | -11.95% |
| 2004-12-31 | $46.1 M | |
| 2002-12-31 | $18.63 M | -67.71% |
| 2001-12-31 | $57.71 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $128.53 B | 11,178.14% | 🇺🇸 USA |
 Merck MRK | $65.42 B | 5,640.55% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $57.22 B | 4,920.98% | 🇬🇧 UK |
 Soligenix SNGX | $7.29 M | -99.36% | 🇺🇸 USA |
 SIGA Technologies SIGA | $78.15 M | -93.14% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $30.23 M | -97.35% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $35.23 B | 2,991.16% | 🇮🇱 Israel |